MIM
STRO icon

MetLife Investment Management’s Sutro Biopharma STRO Stock Holding History

MetLife Investment Management’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,339
Closed -$43K – 2823
2024
Q4 		$43K Sell
2,339
-751
-24% -$22.9K ﹤0.01% 2750
2024
Q3 		$107K Sell
3,090
-1,769
-36% -$69.3K ﹤0.01% 2597
2024
Q2 		$142K Buy
4,859
+1,831
+60% +$72.4K ﹤0.01% 2436
2024
Q1 		$171K Buy
3,028
+190
+7% +$8.39K ﹤0.01% 2278
2023
Q4 		$122K Hold
2,838
– – ﹤0.01% 2504
2023
Q3 		$98.5K Hold
2,838
– – ﹤0.01% 2585
2023
Q2 		$132K Hold
2,838
– – ﹤0.01% 2521
2023
Q1 		$131K Hold
2,838
– – ﹤0.01% 2442
2022
Q4 		$229K Buy
2,838
+430
+18% +$29.9K ﹤0.01% 2162
2022
Q3 		$134K Buy
2,408
+2,072
+617% +$123K ﹤0.01% 2536
2022
Q2 		$17.5K Sell
336
-2,214
-87% -$124K ﹤0.01% 2847
2022
Q1 		$210K Buy
2,550
+908
+55% +$86.4K ﹤0.01% 2329
2021
Q4 		$244K Hold
1,642
– – ﹤0.01% 1936
2021
Q3 		$310K Hold
1,642
– – ﹤0.01% 1805
2021
Q2 		$305K Buy
1,642
+334
+26% +$65.4K ﹤0.01% 1875
2021
Q1 		$298K Buy
1,308
+50
+4% +$11.9K ﹤0.01% 1815
2020
Q4 		$273K Hold
1,258
– – ﹤0.01% 1817
2020
Q3 		$126K Buy
+1,258
New +$119K ﹤0.01% 2104

Other funds holding STRO

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

MetLife Investment Management's STRO Position: Q1 2025 in Review

MetLife Investment Management sold out of Sutro Biopharma (STRO) in Q1 2025, closing a stake of 2,339 shares — an estimated $43K sold.

MetLife Investment Management first reported a position in STRO in Q3 2020 and held it in 18 quarters. The position peaked at $310K in Q3 2021. 112 funds tracked by Wall St. Rank hold STRO as of Q1 2025.

  • MetLife Investment Management reported no remaining Sutro Biopharma position as of Q1 2025 after selling out during the quarter.
  • MetLife Investment Management sold 2,339 Sutro Biopharma shares in Q1 2025, an estimated $43K.
  • MetLife Investment Management first reported a position in Sutro Biopharma in Q3 2020 and held it in 18 quarters.
  • MetLife Investment Management's Sutro Biopharma position peaked at $310K in Q3 2021.
  • 112 funds tracked by Wall St. Rank held Sutro Biopharma as of Q1 2025.

Based on MetLife Investment Management's 13F filing for Q1 2025, filed 14 May 2025.